Literature DB >> 10729287

Disease and "dis-ease" in patients with uveal melanoma.

B Damato.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10729287      PMCID： PMC1723436          DOI： 10.1136/bjo.84.4.343

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  6 in total

1.  Mode of presentation and time to treatment of uveal melanoma in Finland.

Authors:  S Eskelin; T Kivelä
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

2.  Quality of life in the follow-up of uveal melanoma patients after enucleation in comparison to CyberKnife treatment.

Authors:  A Klingenstein; C Fürweger; A K Mühlhofer; S F Leicht; U C Schaller; A Muacevic; B Wowra; C Hintschich; K H Eibl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-11-16       Impact factor: 3.117

3.  Quality of life and cancer-related needs in patients with choroidal melanoma.

Authors:  Joshua F Wiley; Kelsey Laird; Tammy Beran; Tara A McCannel; Annette L Stanton
Journal:  Br J Ophthalmol       Date:  2013-09-13       Impact factor: 4.638

4.  Psychological Reactions and Persistent Facial Pain following Enucleation.

Authors:  Dominic Hegarty; Daniel Coakley; Ian Dooley
Journal:  Pain Res Treat       Date:  2014-04-23

5.  Mapping research trends of uveal melanoma: a bibliometric analysis.

Authors:  Senmao Li; Yongwei Guo; Xiaoyi Hou; Jinhua Liu; Wanlin Fan; Sitong Ju; Philomena A Wawer Matos; Alexander C Rokohl; Ludwig M Heindl
Journal:  Int Ophthalmol       Date:  2021-11-05       Impact factor: 2.031

6.  Beta1-6 branching of cell surface glycoproteins may contribute to uveal melanoma progression by up-regulating cell motility.

Authors:  Małgorzata Przybyło; Ewa Pocheć; Paweł Link-Lenczowski; Anna Lityńska
Journal:  Mol Vis       Date:  2008-03-26       Impact factor: 2.367
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.